These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33672357)

  • 21. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 22. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
    Riquelme E; Behrens C; Lin HY; Simon G; Papadimitrakopoulou V; Izzo J; Moran C; Kalhor N; Lee JJ; Minna JD; Wistuba II
    Cancer Res; 2016 Feb; 76(3):675-85. PubMed ID: 26676756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
    Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of real-life data from patients with NGS panel negative and
    Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
    Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
    J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
    Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
    Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
    Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
    Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
    Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
    Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of wild type KRAS in KRAS
    Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
    Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 37. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
    Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
    Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
    Meeusen B; Cortesi EE; Domènech Omella J; Sablina A; Ventura JJ; Janssens V
    Cancer Lett; 2021 Nov; 520():57-67. PubMed ID: 34216687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.